CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
HD-tDCSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04817891
NCT04817891N/ACompleted
CompareCT.gov

Cholinergic Functions and Modulation of the Cingulo-opercular Alertness Network in LBD

University of Michigan·interventional·Posted Mar 26, 2021·Updated Oct 22, 2025

In Brief

A clinical study evaluating HD-tDCS for Lewy Body Disease and 2 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

Fluctuations in alertness are very common in persons with Lewy body dementias and are a major source of disability. Changes in a chemical messenger molecule called acetylcholine within certain brain regions may play a role in these fluctuations. We propose to test this hypothesis and also determine whether a non-invasive way of stimulating affected brain regions may be of relevance for future management of these fluctuations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLewy Body Disease, Lewy Body Variant of Alzheimer Disease, Lewy Body Dementia With Behavioral Disturbance
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 26, 2021
Enrollment StartMay 3, 2021
Primary CompletionAug 26, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.3 years ago

Interventions

HD-tDCSdevice

Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.